Chemical warfare and the Gulf War: A review of the impact on gulf veterans' health

Military Medicine

Volumn 168, Issue 8, 2003, Pages 606-613

  Riddle, James R ^a,e   Brown, Mark ^b   Smith, Tyler ^c   Ritchie, Elspeth Cameron ^a   Brix, Kelley Ann ^b   Romano, James ^d  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^e Skyline Six   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GAS; NEUROTOXIN; ORGANOPHOSPHATE PESTICIDE; SARIN; SOMAN; TABUN;

ACUTE TOXICITY; CHEMICAL WARFARE; CHRONIC TOXICITY; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HUMAN; IRAN; NEUROTOXICITY; OCCUPATIONAL EXPOSURE; REVIEW; SOLDIER; WAR;

EID: 0043076349     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.1093/milmed/168.8.606     Document Type: Review

References (160)

1. Bendor A, Gelkopf M., Sigal M: Insanity and war: the Gulf War and a psychiatric institution. Am J Psychother 1993; 47: 57-63.
2. Waters L: Chemical weapons in the Iran/Iraq war. Milit Rev 1990.
3. Central Intelligence Agency: Persian Gulf War Illnesses Task Force: Kamisiyah: a Historical Perspective on Related Intelligence, April 1997.
4. Central Intelligence Agency: Iraq as a Military Adversary. November, 1990.
5. Operation Desert Storm: Evaluation of the Air Campaign. Letter report GAO/NSIAD-97-134, June 12, 1997.
6. Greene S: Push for Gulf syndrome research. Nature 1993; 364: 659.
7. U.S. Senate Committee on Banking, Housing, and Urban Affairs: Chemical and Biological Warfare-Related Dual Use Exports to Iraq and Their Possible Impact on the Health Consequences of the Persian Gulf War. Washington. DC, U.S. Senate, 1994.
8. Office of the Special Assistant for Gulf War Illnesses: Case Narrative: U.S. Demolition Operations at Khamisiyah. 2000.
9. Office of the Special Assistant for Gulf War Illnesses: Library of Case Narratives, Environmental Exposure Reports, Information Papers, Close Out Reports, and Studies and Analysis, 2002. Available at http://www.gulflink.osd.mil/library/osagwi_reports.html: accessed June 2002.
10. Korenyi-Both AL, Sved L, Korenyi-Both GE, Juncer DJ, Szekely A: The role of the sand in chemical warfare agent exposure among Persian Gulf War veterans: Al Eskan disease and "dirty dust." Milit Med 2000; 165: 321-36.
11. Haley RW, Billecke S, La Du BN: Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 1999; 157: 227-33.
12. Brown MA, Brix KA: Review of health consequences from high-, intermediate-and low-level exposure to organophosphorus nerve agents. J Appl Toxicol 1998; 18: 393-408.
13. Barrett DS, Oehme FW, Kruckenberg SM: A review of organophosphorus ester-induced delayed neurotoxicity. Vet Hum Toxicol 1985; 27: 22-37.
14. Dettbarn WD: Pesticide induced muscle necrosis: mechanisms and prevention. Fundam Appl Toxicol 1984; 4: S18-S26.
15. Holstege CP, Kirk M, Sidell FR: Chemical warfare: nerve agent poisoning. Crit Care Clin 1997; 13: 923-42.
16. Karalliedde L, Henry JA: Effects of organophosphates on skeletal muscle. Hum Exp Toxicol 1993; 12: 289-96.
17. Gunderson CH, Lehmann CR, Sidell FR, Jabbari B: Nerve agents: a review. Neurology 1992; 42: 946-50.
18. Ray DE: Chronic effects of low level exposure to anticholinesterases: a mechanistic review. Toxicol Lett 1998; 102-103, 527-33.
19. National Research Council, Panel on Anticholinesterase, Panel on Anticholinergic Chemicals, Committee on Toxicology, Board on Toxicology and Environmental Health Hazards: Possible Long-Term Effects of Short-Term Exposure to Chemical Agents, Vol 1. Washington, DC, National Academy Press, 1999.
20. U.S. Department of Health Human Services, Centers for Disease Control, Public Health Service: Final Recommendations for Protecting the Health and Safety against Potential Adverse Effects of Long-Term Exposure to Low Doses of Agents: GA, GB, VX, Mustard Gas (H, HD, T) and Lewisite(L). 53 FR 8504. Washington, DC, National Academy Press, 1988.
21. National Research Council: Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents. Washington, DC, National Academy Press, 1985.
22. National Research Council: Review of Acute Human-Toxicity Estimates for Selected Chemical-Warfare Agents. Washington, DC, National Academy Press, 1997.
23. Zajtehuk R, Bellamy RF, Sidell FR, Takafuji ET, Franz RD, Davis LB, et al, (editors): Textbook of Milit Med: Medical Aspects of Chemical and Biological Warfare. Washington, DC. Office of the Surgeon General at TMM Publications, Borden Institute, Walter Reed Army Medical Center, 1997.
24. Ballantyne B, Marrs TC, (editors): Clinical and Experimental Toxicology of Organophosphates and Carbamates. Boston, Butterworth-Heinemann, 1992.
25. Hartgraves SL, Murphy MR: Behavioral effects of low-dose nerve agents. In: Chemical Warfare Agents, pp 125-153. Edited by Somani S. London, Academic Press, 1992.
26. Somani S: Chemical Warfare Agents. London, Academic Press, 1992.
27. Marrs TC, Maynard RL, Sidell FR: A history of human studies with nerve agents by the UK and USA. In: Chemical Warfare Agents, Chap 5, Chichester, England, John Wiley & Sons, 1996.
28. Perrotta D: Long-term health effects associated with sub-clinical exposures to GB and mustard. Armed Forces Epidemiological Board, 1996. Available at http://www.ha.osd.mil/afeb/reports/mustard%20gas.pdf.
29. Elson E: Report on possible effects of organophosphate "low-level" nerve agent exposure. Memorandum for the Deputy Assistant Secretary of Defense for Health Affairs (Clinical Services), 1997.
30. Jacobsen K, Christensen MK, DeArmon IA, Oberst FW: Studies of chronic exposure to dogs to GB(isopropyl methylphosphonofluofidate) vapor. Arch Indust Health 1959; 19: 5-10.
31. Minton NA, Murray VS: A review of organophosphate poisoning. Med Toxicol Adverse Drug Exp 1988; 3: 350-75.
32. Somani SM, Romano JA: Chemical Warfare Agents: Toxicology at Low Levels. Cleveland, OH, CRC LLC, 2001.
33. Lotti M: Low-level exposures to organophosphorus esters and peripheral nerve function. Muscle Nerve 2002; 25: 492-504.
34. Morita H: [Neurotoxicity of nerve agents]. No To Shinkei 1995; 47: 1129-34.
35. Pearce PC, Crofts HS, Muggleton NG, Ridout D, Scott EA: The effects of acutely administered low dose sarin on cognitive behaviour and the electroencephalogram in the common marmoset. J Psychopharmacol 1999; 13: 128-35.
36. Kelly SS, Ferry CB, Bamforth JP: The effects of anticholinesterases on the latencies of action potentials in mouse skeletal muscles. Br J Pharmacol 1990; 99: 721-6.
37. Levin HS, Rodnitzky RL: Behavioral effects of organophosphate in man. Clin Toxicol 1976; 9: 391-403.
38. Levin HS, Rodnitzky RL, Mick DL: Anxiety associated with exposure to organophosphate compounds. Arch Gen Psychiatry 1976; 33: 225-8.
39. Rodnitzky RL: Occupational exposure to organophosphate pesticides: a neurobehavioral study. Arch Environ Health 1975; 30: 98-103.
40. Sidell FR: Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol 1974; 7: 1-17.
41. Burchfiel JL, Duffy FH: Organophosphate neurotoxicity: chronic effects of sarin on the electroencephalogram of monkey and man. Neurobehav Toxicol Teratol 1982; 4: 767-78.
42. Burchfiel JL, Duffy FH, Van Sim M: Persistent effects of sarin and dieldrin upon the primate electroencephalogram. Toxicol Appl Pharmacol 1976; 35: 365-79.
43. Duffy FH, Burchfiel JL, Bartels PH, Gaon M, Sim VM: Long-term effects of an organophosphate upon the human electroencephalogram. Toxicol Appl Pharmacol 1979; 47: 161-76.
44. Okumura T, Takasu N, Ishimatsu S, et al: Report on 640 victims of the Tokyo subway sarin attack. Ann Emerg Med 1996; 28: 129-35.
45. Ohbu S, Yamashina A, Takasu N, et al: Sarin poisoning on Tokyo subway. South Med J 1997; 90: 587-93.
46. Yokoyama K, Araki S, Murata K, et al: Chronic neurobehavioral and central and autonomic nervous system effects of Tokyo subway sarin poisoning. J Physiol Paris 1998; 92: 317-23.
47. Yokoyama K, Araki S, Murata K, et al: A preliminary study on delayed vestibulo-cerebellar effects of Tokyo Subway Sarin Poisoning in relation to gender difference: frequency analysis of postural sway. J Occup Environ Med 1998; 40: 17-21.
48. Yokoyama K, Araki S, Murata K, et al: Chronic neurobehavioral effects of Tokyo subway sarin poisoning in relation to posttmumatic stress disorder. Arch Environ Health 1998; 53: 249-56.
49. Mutch E, Blain PG, Williams FM: Interindividual variations in enzymes controlling organophosphate toxicity in man. Hum Exp Toxicol 1992; 11: 109-16.
50. Clegg DJ, van Gemert M: Expert panel report of human studies on chlorpyrifos and/or other organophosphate exposures. J Toxicol Environ Health B Crit Rev 1999; 2: 257-79.
51. Johnson MK: Organophosphates and delayed neuropathy - is NTE alive and well? Toxicol Appl Pharmacol 1990; 102: 385-99.
52. Glynn P: Neuropathy target esterase. Biochem J 1999; 344: 625-31.
53. Gordon JJ, Inns RH, Johnson MK, et al: The delayed neuropathic effects of nerve agents and some other organophosphorus compounds. Arch Toxicol 1983; 52: 71-82.
54. Munro NB, Ambrose KR, Watson AP: Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: implications for public protection. Environ Health Perspect 1994; 102: 18.
55. Gerr F: Health Effects of Neurotoxic Agents Used in the Persian Gulf War. A Report to the Committee on Veterans' Affairs of the United States Senate. Washington, DC, U.S. Senate, 1998.
56. National Research Council: Review of the U.S. Army's Health Risk Assessments for Oral Exposure to Six Chemical Warfare Agents. Washington, DC, National Academy Press, 1999.
57. Moore DH: Health effects of exposure to low doses of nerve agent: a review of present knowledge. Drug Chem Toxicol 1998; 21(Suppl 1): 123-30.
58. Nakajima T, Sato S, Morita H, Yanagisawa N: Sarin poisoning of a rescue team in the Matsumoto sarin incident in Japan. Occup Environ Med 1997; 54: 697-701.
59. Institute of Medicine: GulfWar and Health, Vol I. Depleted Uranium, Pyridostigmine Bromide, Sarin, Vaccines. Committee on Health Effects Associated with Exposures during the Gulf War. Washington, DC, National Academy Press, 2000.
60. Gray GC, Kaiser KS, Hawksworth AW, Hall FW, Barrett-Connor E: Increased postwar symptoms and psychological morbidity among U.S. Navy Gulf War veterans. Am J Trop Med Hyg 1999; 60: 758-66.
61. Gray GC, Smith TC, Kang HK, Knoke JD: Are Gulf War veterans suffering war-related illnesses? Federal and civilian hospitalizations examined, June 1991 to December 1994. Am J Epidemiol 2000; 151: 63-71.
62. Gray GC, Coate BD, Anderson CM, et al: The postwar hospitalization experience of U.S. veterans of the Persian Gulf War. N Engl J Med 1996; 335: 1505-13.
63. Kang HK, Mahan CM, Lee KY, Magee CA, Murphy FM: Illnesses among United States veterans of the Gulf War: a population-based survey of 30,000 veterans. J Occup Environ Med 2000; 42: 491-501.
64. Kang HK, Bullman TA: Mortality among U.S. veterans of the Persian Gulf War. N Engl J Med 1996; 335: 1498-1504.
65. Joseph SC: A comprehensive clinical evaluation of 20,000 Persian Gulf War veterans: Comprehensive Clinical Evaluation Program Evaluation Team. Milit Med 1997; 162: 149-55.
66. Roy MJ, Koslowe PA, Kroenke K, Magruder C: Signs, symptoms, and ill-defined conditions in Persian Gulf War veterans: findings from the Comprehensive Clinical Evaluation Program. Psychosom Med 1998; 60: 663-8.
67. Kang HK, Bullman TA: Mortality among U.S. veterans of the Persian Gulf War: 7-year follow-up. Am J Epidemiol 2001; 154: 399-405.
68. Knoke JD, Gray GC: Hospitalizations for unexplained illnesses among U.S. veterans of the Persian Gulf War. Emerg Infect Dis 1998; 4: 211-9.
69. Gray GC, Smith TC, Knoke JD, Heller JM: The postwar hospitalization experience of Gulf War veterans possibly exposed to chemical munitions destruction at Khamisiyah, Iraq. Am J Epidemiol 1999; 150: 532-40.
70. Newmark J. Clayton WR: Persian Gulf illnesses: preliminary neurological impressions. Milit Med 1995; 160: 505-7.
71. Steele L: Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol 2000; 152: 992-1002.
72. Goss Gilroy Inc., Management Consultants Gulf War Illness Advisory Committee: Department of National Defence Health Study of Canadian Forces Personnel Involved in the 1991 Conflict in the Persian Gulf War, Vol I. Ottawa, ON, Candada, Goss Gilroy Inc., 1998.
73. The Iowa Persian Gulf Study Group: Self-reported illness and health status among GulfWar veterans: a population-based study. JAMA 1997; 277: 238-45.
74. Fukuda K, Nisenbaum R, Stewart G, et al: Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA 1998; 280: 981-8.
75. Proctor SP, Heeren T, White RF, et al: Health status of Persian Gulf War veterans: self-reported symptoms, environmental exposures and the effect of stress. Int J Epidemiol 1998; 27: 1000-10.
76. Unwin C, Blatchley N, Coker W, et al: Health of UK servicemen who served in Persian Gulf War. Lancet 1999: 353: 169-78.
77. Dlugosz L, Hocter WJ, Kaiser KS, et al: Risk factors for mental disorder hospitalization after the Persian Gulf War: U.S. Armed Forces, June 1, 1991-September 30, 1993. J Clin Epidemiol 1999; 52: 1267-78.
78. Nisenbaum R, Barrett DH, Reyes M, Reeves WC: Deployment stressors and a chronic multisymptom illness among Gulf War veterans. J Nerv Merit Dis 2000; 188: 259-66.
79. Spencer PS, McCauley LA, Lapidus JA, Lasarev M, Joos SK, Storzbach D: Self-reported exposures and their association with unexplained illness in a population-based case-control study of Gulf War veterans. J Occup Environ Med 2001; 43: 1041-56.
80. Brandt GT, Norwood AE, Ursano RJ, et al: Psychiatric morbidity in medical and surgical patients evacuated from the Persian GulfWar. Psychiatr Serv 1997; 48: 102-4.
81. Haley RW, Kurt TL: Self-reported exposure to neurotoxic chemical combinations in the Gulf War: a cross-sectional epidemiologic study. JAMA 1997; 277: 231-7.
82. Kroenke K, Koslowe P, Roy M: Symptoms in 18,495 Persian Gulf War veterans: latency of onset and lack of association with self-reported exposures. J Occup Environ Med 1998; 40: 520-8.
83. Joellenbeck LM, Landrigan PJ, Larson EL: Gulf War veterans' illnesses: a case study in causal inference. Environ Res 1998; 79: 71-81.
84. Perconte ST, Wilson AT, Pontius EB, Dietrick AL, Spiro KJ: Psychological and war stress symptoms among deployed and non-deployed reservists following the Persian Gulf War. Milit Med 1993; 158: 516-21.
85. Southwick SM, Morgan A, Nagy LM, et al: Trauma-related symptoms in veterans of Operation Desert Storm: a preliminary report. Am J Psychiatry 1993; 150: 1524-8.
86. NIH Technology Assessment Workshop Panel: The Persian Gulf experience and health. JAMA 1994; 272: 391-6.
87. United States Senate Committee on Veteran's Affairs: Report of the Special Investigation Unit on Gulf War Illnesses. Washington, DC, U.S. Government Printing Office, 1998.
88. Coughlin SS: Recall bias in epidemiologic studies. J Clin Epidemiol 1990; 43: 87-91.
89. Stretch RH, Bliese PD, Marlowe DH, Wright KM, Knudson KH, Hoover CH: Psychological health of Gulf War-era military personnel. Milit Med 1996; 161: 257-61.
90. Stretch RH, Marlowe DH, Wright KM, Bliese PD, Knudson KH, Hoover CH: Post-traumatic stress disorder symptoms among Gulf War veterans. Milit Med 1996; 161: 407-10.
91. Baker DG, Mendenhall CL, Simbartl LA, Magan LK, Steinberg JL: Relationship between posttraumatic stress disorder and self-reported physical symptoms in Persian Gulf War veterans. Arch Intern Med 1997; 157: 2076-8.
92. Wolfe J, Proctor SP, Davis JD, Borgos MS, Friedman MJ: Health symptoms reported by Persian Gulf War veterans two years after return. Am J Ind Med 1998; 33: 104-13.
93. Schumm W, Reppert EJ, Jurich AP, et al: Pyridostigmine bromide and the long-term subjective health status of a sample of female reserve component Gulf War veterans: a brief report. Psychol Rep 2001; 88: 306-8.
94. Ismail K, Everitt B, Blatchley N, et al: Is there a Gulf War syndrome? Lancet 1999; 353: 179-82.
95. Doebbeling BN, Clarke WR, Watson D, et al: Is there a Persian Gulf War syndrome: evidence from a large population-based survey of veterans and nondeployed controls. Am J Med 2000; 108: 695-704.
96. McCauley LA, Joos SK, Lasarev MR, Storzbach D, Bourdette DN: Gulf War unexplained illnesses: persistence and unexplained nature of self-reported symptoms. Environ Res 1999; 81: 215-23.
97. McCauley LA, Joos SK, Spencer PS, Lasarev M, Shuell T: Strategies to assess validity of self-reported exposures during the Persian Gulf War. Portland Environ Hazards Res Center Environ Res 1999; 81: 195-205.
98. Haley RW, Kurt TL, Hom J: Is there a Gulf War syndrome: searching for syndromes by factor analysis of symptoms. JAMA 1997; 277: 215-22.
99. Samet M: Letter to Presidential Oversight Board, 1999.
100. Amato AA, McVey A, Cha C, et al: Evaluation of neuromuscular symptoms in veterans of the Persian Gulf War. Neurology 1997; 48: 4-12.
101. Anger WK, Storzbach D, Binder LM, et al: Neurobehavioral deficits in Persian Gulf veterans: evidence from a population-based study. Portland Environ Hazards Res Center J Int Neuropsychol Soc 1999; 5: 203-12.
102. Axelrod BN, Milner IB: Neuropsychological findings in a sample of Operation Desert Storm veterans. J Neuropsychiatry Clin Neurosci 1997; 9: 23-8.
103. Goldstein G, Beers SR, Morrow LA, Shemansky WJ, Steinhauer SR: A preliminary neuropsychological study of Persian Gulf veterans. J Int Neuropsychol Soc 1996; 2: 368-71.
104. Haley RW, Hom J, Roland PS, et al: Evaluation of neurologic function in Gulf War veterans: a blinded case-control study. JAMA 1997; 277: 223-30.
105. Jamal GA, Hansen S, Apartopoulos F, Peden A: The "Gulf War syndrome": is there evidence of dysfunction in the nervous system? J Neurol Neurosurg Psychiatry 1996; 60: 449-51.
106. Kurt TL: Epidemiological association in U.S. veterans between Gulf War Illness and exposures to anticholinesterases. Toxicol Lett 1998; 102-3: 523-6.
107. Roland PS, Haley RW, Yellin W, Owens K, Shoup AG: Vestibular dysfunction in Gulf War syndrome. Otolaryngol Head Neck Surg 2000; 122: 319-29.
108. Sillanpaa MC, Agar LM, Axelrod BN: Minnesota Multiphasic Personality Inventory-2 validity patterns: an elucidation of Gulf War syndrome. Milit Med 1999; 164: 261-3.
109. Sillanpaa MC, Agar LM, Milner IB, Podany EC, Axelrod BN, Brown GG: Gulf War veterans: a neuropsychological examination. J Clin Exp Neuropsychol 1997; 19: 211-9.
110. Suadicani P, Ishoy T, Guldager B, Appleyard M, Gyntelberg F: Determinants of long-term neuropsychological symptoms. Dan Gulf War Study Dan Med Bull 1999; 46: 423-7.
111. White RF, Proctor SP, Heeren T, et al: Neuropsychological function in Gulf War veterans: relationships to self-reported toxicant exposures. Am J Ind Med 2001; 40: 42-54.
112. Kotler-Cope S, Milby J, Roswell R, et al: Neuropsychological Functioning in Persian Gulf War Veterans: a Preliminary Report, Annual Meeting of the International Neuropsychological Society, Orlando, FL, 1996.
113. Kotler S, Dymek M: Emotional Distress and Neuropsychological Functioning in Persian Gulf War Veterans, Annual Meeting of the International Neuropsychological Society, Orlando, FL, 1997.
114. Bourdette DN, McCauley LA, Barkhuizen A, et al: Symptom factor analysis, clinical findings, and functional status in a population-based case control study of Gulf War unexplained illness. J Occup Environ Med 2001; 43: 1026-40.
115. Storzbach D, Rohlman DS, Anger WK, Binder LM, Campbell KA: Neurobehavioral deficits in Persian Gulf veterans: additional evidence from a population-based study. Environ Res 2001; 85: 1-13.
116. Storzbach D, Campbell KA, Binder LM, et al: Psychological differences between veterans with and without Gulf War unexplained symptoms. Portland Environ Hazards Res Center Psychosom Med 2000; 62: 726-35.
117. Lange G, Tiersky LA, Scharer JB, et al: Cognitive functioning in Gulf War illness. J Clin Exp Neuropsychol 2001; 23: 240-9.
118. Albers J, Berent S: Controversies in neurotoxicology: current status. Neurol Clin 2000; 18: 741-64.
119. Landrigan PJ: Identification of Gulf War syndrome: methological issues and medical illnesses [Letters]. JAMA 1997; 278: 383-7.
120. Gray GC, Knoke JD, Berg SW, Wignall FS, Barrett-Connor E: Counterpoint: responding to suppositions and misunderstandings. Am J Epidemiol 1998; 148: 328-33.
121. Engel Jr CC, Jing Z: Identification of Gulf War syndrome: methodological issues and medical illnesses. JAMA 1997; 278: 383-7.
122. Hyams KC, Wignall FS: Identification of Gulf War syndrome: methodological issues and medical illnesses. JAMA 1997; 278: 384-7.
123. Amato A, Jackson C, McVey A: Identification of Gulf War syndrome: methodological issues and medical illnesses. JAMA 1997; 278: 384-7.
124. Gots RE, Schwartz SL, Hershkowitz N, Chaudhry V, Vogel RL: Identification of Gulf War syndrome: methodological issues and medical illnesses. JAMA 1997; 278: 385-7.
125. Landrigan PJ: Illness in Gulf War veterans: causes and consequences. JAMA 1997; 277: 259-61.
126. Knoke JD, Smith TC, Gray GC, Kaiser KS, Hawksworth AW: Factor analysis of self-reported symptoms: does it identify a Gulf War syndrome? Am J Epidemiol 2000; 152: 379-88.
127. Marlow D: Psychological and Psychosocial Consequences of Combat and Deployment with Special Emphasis on the Gulf War. National Defense Research Institute. Santa Monica, CA, RAND, 2001.
128. Hyams KC, Murphy FM, Wessely S: Responding to chemical, biological, or nuclear terrorism: the indirect and long-term health effects may present the greatest challenge. J Health Polit Policy Law 2002; 27: 273-91.
129. Boxer PA: Occupational mass psychogenic illness: history, prevention, and management. J Occup Med 1985; 27: 867-72.
130. Brooks F, Ebner D, Xenakis S, Balson P: Psychological reactions during chemical warfare training. Milit Med 1983; 148: 232-5.
131. Noble D: Back into the storm: reanalyzing health effects of the Gulf War. Anal Chem 1994; 66: 805A-8A.
132. A review of UK forces chemical warfare agent alerts during 1990-1991 Gulf conflict. London, UK, Ministry of Defence, 2000.
133. Huber L: The Poisonous Cloud: Chemical Warfare in the First World War. Oxford, Clarendon Press, 1986.
134. DiGiovanni Jr C: Domestic terrorism with chemical or biological agents: psychiatric aspects. Am J Psychiatry 1999; 156: 1500-5.
135. Ursano R: Combat stress in the chemical and biological warfare environment. Aviat Space Environ Med 1992; 3018: 92.
136. Bennett P, Calman K: Risk communication and public health. In: Oxford Medical Publications, Vol XXIV, p 272. Oxford, Oxford University Press, 1999.
137. Falkenrath R: Confronting nuclear, biological, and chemical terrorism. Survival 1998; 40: 43-65.
138. Holloway HC, Norwood AE, Fullerton CS, Engel Jr CC, Ursano RJ: The threat of biological weapons: prophylaxis and mitigation of psychological and social consequences. JAMA 1997; 278: 425-7.
139. Singer TJ: An introduction to disaster: some considerations of a psychological nature. Aviat Space Environ Med 1982; 53: 245-50.
140. Ursano RJ, Fullerton CS, Norwood AE: Psychiatric dimensions of disaster: patient care, community consultation, and preventive medicine. Harv Rev Psychiatry 1995; 3: 196-209.
141. Ritchie EC: Treatment of gas mask phobia. Milit Med 1992; 157; 104-6.
142. Ursano RJ, Holloway HC, Jones DR, Rodriguez AR, Belenky GL: Psychiatric care in the military community: family and military stressors. Hosp Commun Psychiatry 1989; 40: 1284-9.
143. Fullerton CS, Ursano RJ: Behavioral and psychological responses to chemical and biological warfare. Milit Med 1990; 155: 54-9.
144. O'Brien LS, Payne RG: Prevention and management of panic in personnel facing a chemical threat: lessons from the Gulf War. J R Army Med Corps 1993; 139: 41-5.
145. Took KJ: Gas mask phobia. Milit Med 1992; 157: A10.
146. Deakins DE: Further cases of gas mask phobia. Milit Med 1993; 158: A4.
147. Bleich A, Dycian A, Koslowsky M, Solomon Z, Wiener M: Psychiatric implications of missile attacks on a civilian population: Israeli lessons from the Persian Gulf War. JAMA 1992; 268: 613-5.
148. Canneli A, Liberman N, Mevorach L: Anxiety-related somatic reactions during missile attacks. Isr J Med Sci 1991; 27: 677-80.
149. Office of the Special Assistant for Special Assistant for Gulf War Illnesses, Medical Readiness, and Military Deployments: Case Narrative, Chemical Warfare Agent Release at Muhammadiyat Ammunition Storage Site, 2001. Available at http://www.gulflink.osd.mil/new_index.html.
150. Marrs TC: Organophosphate poisoning. Pharmacol Ther 1993; 58: 51-66.
151. National Research Council, Panel on Anticholinesterase Chemicals. Panel on Anticholinergic Chemicals, Committee on Toxicology, Board on Toxicology and Environmental Health Hazards: Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents, Vol 1. ISBN POD090. Washington, DC, National Academy Press, 1982.
152. National Research Council, Committee on Toxicology: Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents, Vol 2: Cholinesterase Reactivators, Psychochemicals and Irritants and Vesicants. ISBN NI000070. Washington DC, National Academy Press, 1984.
153. Ford JD, Campbell KA, Storzbach D, Binder LM, Anger WK, Rohlman DS: Post-traumatic stress symptomatology is associated with unexplained illness attributed to Persian Gulf War military service. Psychosom Med 2001; 63: 842-9.
154. Glaustusz J: A syndrome for every war. Discover 2002; 23: 12.
155. Jones E, Hodgins-Vermaas R, McCartney H, et al: Post-combat syndromes from the Boer war to the Gulf War: a cluster analysis of their nature and attribution. BMJ 2002; 324: 397.
156. Hyams KC, Wignall FS, Roswell R: War syndromes and their evaluation: from the U.S. Civil War to the Persian Gulf War. Ann Intem Med 1996; 125: 398-405.
157. Pearn J: Traumatic stress disorders: a classification with implications for prevention and management. Milit Med 2000; 165: 434-40.
158. Persian Gulf Veterans Coordinating Board: Unexplained illnesses among Desert Storm veterans: a search for causes, treatment, and cooperation. Arch Intern Med 1995; 155: 262-8.
159. Polhuijs M, Langenberg J, Benschop H: New method for retrospective detection of exposure to organophosphorus anticholinesterases: application to alleged sarin victims of Japanese terrorists. Toxicol Appl Pharmacol 1997; 146: 156-61.
160. Department of Defense: DoD Strategy to Address Low-Level Exposures to Chemical Warfare Agents, Washington, DC, Department of Defense, The Pentagon, 1999.